Imperial College London
Portrait Picture

Professor Anthony Gordon

Faculty of Medicine, Department of Surgery & Cancer

Chair in Anaesthesia and Critical Care
 
 
 
//

Contact

 

anthony.gordon

 
 
//

Location

 

ICUQueen Elizabeth the Queen Mother Wing (QEQM)St Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Sterne:2020:10.1186/s13063-020-04641-3,
author = {Sterne, JAC and Diaz, J and Villar, J and Murthy, S and Slutsky, AS and Perner, A and Juni, P and Angus, DC and Annane, D and Pontes, Azevedo LC and Du, B and Dequin, P-F and Gordon, AC and Green, C and Higgins, JPT and Horby, P and Landray, MJ and Lapadula, G and Le, Gouge A and Leclerc, M and Savovic, J and Tomazini, B and Venkatesh, B and Webb, S and Marshall, JC},
doi = {10.1186/s13063-020-04641-3},
journal = {Trials},
pages = {1--3},
title = {Corticosteroid therapy for critically ill patients with COVID-19: A structured summary of a study protocol for a prospective meta-analysis of randomized trials},
url = {http://dx.doi.org/10.1186/s13063-020-04641-3},
volume = {21},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - ObjectivesPrimary objective: To estimate the effect of corticosteroids compared with usual care or placebo on mortality up to 28 days after randomization. Secondary objectives: To examine whether the effect of corticosteroids compared with usual care or placebo on mortality up to 28 days after randomization varies between subgroups related to treatment characteristics, disease severity at the time of randomization, patient characteristics, or risk of bias. To examine the effect of corticosteroids compared with usual care or placebo on serious adverse events.Study designProspective meta-analysis of randomized controlled trials. Both placebo-controlled and open-label trials are eligible.ParticipantsHospitalised, critically ill patients with suspected or confirmed COVID-19.Intervention and comparatorIntervention groups will have received therapeutic doses of a steroid (dexamethasone, hydrocortisone or methylprednisolone) with IV or oral administration immediately after randomization.The comparator groups will have received standard of care or usual care or placebo.Main outcomeAll-cause mortality up to 28 days after randomization.Search methodsSystematic searching of clinicaltrials.gov, EudraCT, the WHO ISRCTN registry, and the Chinese clinical trials registry. Additionally, research and WHO networks will be asked for relevant trials.Risk of bias assessmentsThese will be based on the Cochrane RoB 2 tool, and will use structured information provided by the trial investigators on a form designed for this prospective meta-analysis.Summary of findingsWe will use GRADE to assess the certainty of the evidence.Statistical analysesTrial investigators will provide data on the numbers of participants who did and did not experience each outcome according to intervention group, overall and in specified subgroups. We will conduct fixed-effect (primary analysis) and random-effects (Paule-Mandel estimate of heterogeneity and Hartung-Knapp adjustment) meta-analyses. We will quantify in
AU  - Sterne,JAC
AU  - Diaz,J
AU  - Villar,J
AU  - Murthy,S
AU  - Slutsky,AS
AU  - Perner,A
AU  - Juni,P
AU  - Angus,DC
AU  - Annane,D
AU  - Pontes,Azevedo LC
AU  - Du,B
AU  - Dequin,P-F
AU  - Gordon,AC
AU  - Green,C
AU  - Higgins,JPT
AU  - Horby,P
AU  - Landray,MJ
AU  - Lapadula,G
AU  - Le,Gouge A
AU  - Leclerc,M
AU  - Savovic,J
AU  - Tomazini,B
AU  - Venkatesh,B
AU  - Webb,S
AU  - Marshall,JC
DO  - 10.1186/s13063-020-04641-3
EP  - 3
PY  - 2020///
SN  - 1745-6215
SP  - 1
TI  - Corticosteroid therapy for critically ill patients with COVID-19: A structured summary of a study protocol for a prospective meta-analysis of randomized trials
T2  - Trials
UR  - http://dx.doi.org/10.1186/s13063-020-04641-3
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000567186100001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04641-3
UR  - http://hdl.handle.net/10044/1/83895
VL  - 21
ER  -
Download